New Risk • Dec 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$54.7m market cap, or US$35.8m). New Risk • Nov 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$7.9m free cash flow). Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$52.0m market cap, or US$33.8m). 공시 • Nov 05
Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 165,588,236
Price\Range: AUD 0.034
Discount Per Security: AUD 0.00204
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,823,528
Price\Range: AUD 0.034
Discount Per Security: AUD 0.00204
Transaction Features: Subsequent Direct Listing 공시 • Sep 16
Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025 Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australia New Risk • Jul 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$1.3m revenue, or US$865k). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$46.0m market cap, or US$30.0m). 공시 • Mar 31
Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 137,500,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 162,500,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing 공시 • Nov 06
Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024 Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024. 공시 • Nov 01
Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 137,500,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 162,500,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Board Change • Oct 09
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director P. Jull is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. New Risk • Sep 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.5m free cash flow). Negative equity (-CA$5.9m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$26.4m market cap, or US$18.0m). 공시 • Sep 06
Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024 Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024. 공시 • Sep 03
Tryptamine Therapeutics Limited Announces Chief Financial Officer Changes Tryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024. New Risk • Aug 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.5m free cash flow). Negative equity (-CA$5.9m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$32.2m market cap, or US$21.5m). Recent Insider Transactions • Jun 04
MD, CEO & Executive Director recently bought AU$62k worth of stock On the 30th of May, Jason Carroll bought around 3m shares on-market at roughly AU$0.025 per share. This transaction amounted to 8.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jason's only on-market trade for the last 12 months.